Skip to main content
Top
Published in: Clinical Rheumatology 2/2008

01-12-2008 | Case Report

A case of ANCA-associated systemic vasculitis induced by atorvastatin

Authors: Muhammad Haroon, Joe Devlin

Published in: Clinical Rheumatology | Special Issue 2/2008

Login to get access

Abstract

We present a 45-year-old male patient who presented to Accident and Emergency department with a 6-week history of pain and stiffness involving his bilateral legs. Both calves were markedly tender, and he was not able to bear weight. He also complained of numbness involving his left big toe for a few days, which later spread to involve his arms, and tinnitus and hearing loss in his left ear. There were no respiratory, gastrointestinal or urinary symptoms. He had a background history of hypercholesterolemia and was treated with atorvastatin 10 mg for 6 months. His initial investigations showed markedly increased inflammatory markers, and serum antineutrophil cytoplasmic antibody (ANCA) was markedly positive at a titre of 1:160 (P-ANCA). Electromyography and muscle biopsy showed myopathic features. A diagnosis of drug-induced ANCA-associated vasculitis (on the basis of mononeuritis multiplex, sensorineural hearing loss and markedly increased anti-myeloperoxidase (MPO) ANCA) and statin-induced distal myopathy was made. He was treated with three 500 mg doses of methylprednisolone, followed by slowly tapering dose of oral corticosteroids from 30 mg once daily (OD). He was also started on azathioprin (2.5 mg/kg). He had a dramatic improvement of his myalgia, hearing loss and sensory symptoms and went into complete clinical remission. His inflammatory markers rapidly returned to normal, and MPO-ANCA normalised within 3 months of starting immunosuppressive therapy and remained negative on further testing. He is currently on a tapering regimen of corticosteroids (7 mg OD), and after weaning him off corticosteroids, we plan to slowly taper his azathioprin.
Literature
1.
go back to reference Vasconelos OM, Campbell WW (2004) Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 30(6):803–807, (Dec)CrossRef Vasconelos OM, Campbell WW (2004) Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 30(6):803–807, (Dec)CrossRef
2.
go back to reference Zuech P, Pauwels C, Duthoit C, Mery L, Somogyi A, Louboutin A, Veyssier-Belot C (2005) Pravastatin-induced dermatomyositis. Rev Med Interne 26(11):897–902, (Nov)PubMedCrossRef Zuech P, Pauwels C, Duthoit C, Mery L, Somogyi A, Louboutin A, Veyssier-Belot C (2005) Pravastatin-induced dermatomyositis. Rev Med Interne 26(11):897–902, (Nov)PubMedCrossRef
3.
go back to reference Noël B, Panizzon RG (2004) Lupus-like syndrome associated with statin therapy. Dermatology 208(3):276–277PubMedCrossRef Noël B, Panizzon RG (2004) Lupus-like syndrome associated with statin therapy. Dermatology 208(3):276–277PubMedCrossRef
4.
go back to reference Suchak R, Benson K, Swale V (2007) Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin Exp Dermatol 32(5):589–591, (Sep)PubMedCrossRef Suchak R, Benson K, Swale V (2007) Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin Exp Dermatol 32(5):589–591, (Sep)PubMedCrossRef
5.
go back to reference Walker T, McCaffery J, Steinfort C (2007) Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust 186(2):91–94, (Jan 15)PubMed Walker T, McCaffery J, Steinfort C (2007) Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust 186(2):91–94, (Jan 15)PubMed
6.
go back to reference Veyrac G, Cellerin L, Jolliet P (2006) A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins. Therapie 61(1):57–67, (Jan–Feb)PubMedCrossRef Veyrac G, Cellerin L, Jolliet P (2006) A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins. Therapie 61(1):57–67, (Jan–Feb)PubMedCrossRef
7.
go back to reference Hansen KE, Hildebrand JP, Ferguson EE et al (2005) Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165:2671–2676PubMedCrossRef Hansen KE, Hildebrand JP, Ferguson EE et al (2005) Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165:2671–2676PubMedCrossRef
8.
go back to reference Choi KH, Merkel AP, Walker MA, Niles LJ (2000) Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titres of antimyeloperoxidase antibodies. Arthritis Rheum 43:405–413PubMedCrossRef Choi KH, Merkel AP, Walker MA, Niles LJ (2000) Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titres of antimyeloperoxidase antibodies. Arthritis Rheum 43:405–413PubMedCrossRef
Metadata
Title
A case of ANCA-associated systemic vasculitis induced by atorvastatin
Authors
Muhammad Haroon
Joe Devlin
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue Special Issue 2/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1020-z

Other articles of this Special Issue 2/2008

Clinical Rheumatology 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine